---
figid: PMC1892626__RIU009002_0047_fig003
figtitle: Regulation of hypoxia-inducible factor-1A (HIF-1A) and drug interventions
  currently in use
organisms:
- Homo sapiens
pmcid: PMC1892626
filename: RIU009002_0047_fig003.jpg
figlink: /pmc/articles/PMC1892626/figure/F3/
number: F3
caption: Regulation of hypoxia-inducible factor-1α (HIF-1α) and drug interventions
  currently in use. Activation of receptor tyrosine kinase (RTK), such as Rous Sarcoma
  oncogene (SRC) and the human epidermal growth factor receptor 2 (HER2), insulinlike
  growth factor (IGF), and epidermal growth factor (EGF) receptors, stimulate the
  PI3K-AKT-mTOR pathway. These pathways lead to the phosphorylation of S6 kinase and
  4E-BP1. S6 kinase and 4E-BP1 lead to the translation of HIF-1α messenger RNA (mRNA).
  The hypoxia-induced pathway is linked to the VHL dysfunction in renal cell carcinoma
  (RCC). HIF regulates the expression of an array of genes that encode proteins regulating
  angiogenesis, pH, metastatic spread, tumor growth, and glucose transport. The drugs
  currently preferred for the targeted treatment of metastatic RCC are depicted here.
  ATP, adenosine triphosphate; EGFR, EGF receptor; mTOR, mammalian target of rapamycin;
  PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; PI3K, phosphoinositide
  3-kinase, TGF-α, transforming growth factor-α; VEGF, vascular endothelial growth
  factor; VEGFR, VEGF receptor.
papertitle: 'Understanding the Natural Biology of Kidney Cancer: Implications for
  Targeted Cancer Therapy.'
reftext: Tobias Klatte, et al. Rev Urol. 2007 Spring;9(2):47-56.
year: '2007'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9525501
figid_alias: PMC1892626__F3
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC1892626__F3
ndex: 483a7bdc-dee9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC1892626__RIU009002_0047_fig003.html
  '@type': Dataset
  description: Regulation of hypoxia-inducible factor-1α (HIF-1α) and drug interventions
    currently in use. Activation of receptor tyrosine kinase (RTK), such as Rous Sarcoma
    oncogene (SRC) and the human epidermal growth factor receptor 2 (HER2), insulinlike
    growth factor (IGF), and epidermal growth factor (EGF) receptors, stimulate the
    PI3K-AKT-mTOR pathway. These pathways lead to the phosphorylation of S6 kinase
    and 4E-BP1. S6 kinase and 4E-BP1 lead to the translation of HIF-1α messenger RNA
    (mRNA). The hypoxia-induced pathway is linked to the VHL dysfunction in renal
    cell carcinoma (RCC). HIF regulates the expression of an array of genes that encode
    proteins regulating angiogenesis, pH, metastatic spread, tumor growth, and glucose
    transport. The drugs currently preferred for the targeted treatment of metastatic
    RCC are depicted here. ATP, adenosine triphosphate; EGFR, EGF receptor; mTOR,
    mammalian target of rapamycin; PDGF, platelet-derived growth factor; PDGFR, PDGF
    receptor; PI3K, phosphoinositide 3-kinase, TGF-α, transforming growth factor-α;
    VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - ATP8A2
  - PTEN
  - MTOR
  - VHL
  - EIF4E
  - HIF1A
  - EPAS1
  - HIF3A
  - ARNT
  - ARNT2
  - BMAL1
  - CA9
  - CXCR4
  - EGFR
  - SLC2A1
  - KDR
  - FLT1
  - FLT4
  - PDGFRB
  - PDGFRA
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - Temsirolimus
  - Glucose
  - Cancer
  - Lung cancer
---
